13F Holdings
中文EN

VRTX VERTEX PHARMACEUTICALS INC / MA

Pharmaceutical Preparations · Nasdaq · SEC CIK 875320 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.5%
TTM net income YoY8.2%
TTM EPS YoY9.4%
Revenue 3-yr CAGR10.3%
Net income 3-yr CAGR4.6%

Margins

Gross margin85.5%
Operating margin33.2%
Net margin30.7%
FCF margin24.7%
EBITDA margin35.1%

Returns

ROE20.8%
ROA13.8%
ROIC (approx.)21.9%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets36.1%
Debt / equity0.22x
Current ratio2.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio1.0%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$12.00B$11.02B$9.87B$8.93B$7.57B
Cost of revenue$1.65B$1.53B$1.26B$1.08B$904.20M
Gross profit$10.35B$9.49B$8.61B$7.85B$6.67B
R&D expense$3.91B$3.63B$3.16B$2.54B$1.94B
SG&A expense$1.75B$1.46B$1.14B$944.70M$840.10M
Operating income$4.17B-$232.90M$3.83B$4.31B$2.78B
Interest expense$13.30M$30.60M$44.10M$54.80M—
Pretax income$4.64B$248.50M$4.38B$4.23B$2.73B
Income tax$690.00M$784.10M$760.20M$910.40M$388.30M
Net income$3.95B-$535.60M$3.62B$3.32B$2.34B
EBITDA$4.38B-$25.70M$4.01B$4.46B$2.91B
EPS (basic)15.46-2.0814.0512.979.09
EPS (diluted)15.32-2.0813.8912.829.01
Weighted avg. shares (diluted)258.00M257.90M260.50M259.10M259.90M
Banking
Net interest income——-$44.10M-$54.80M-$61.50M
Balance sheet
Cash & equivalents$5.08B$4.57B$10.37B$10.50B$6.79B
Short-term investments$1.52B$1.55B$849.20M$274.50M$729.90M
Receivables$2.05B$1.61B$1.56B$1.44B$1.14B
Inventory$1.69B$1.21B$738.80M$460.60M$353.10M
Current assets$11.20B$9.60B$14.14B$13.23B$9.56B
PP&E, net$1.52B$1.23B$1.16B$1.11B$1.09B
Goodwill$1.09B$1.09B$1.09B$1.09B$1.00B
Intangibles$424.20M$825.90M$839.90M$603.60M$400.00M
Total assets$25.64B$22.53B$22.73B$18.15B$13.43B
Current liabilities$3.86B$3.56B$3.55B$2.74B$2.14B
Short-term debt$0————
Long-term debt$0————
Total debt$0————
Total liabilities$6.98B$6.12B$5.15B$4.24B$3.33B
Shareholders' equity$18.67B$16.41B$17.58B$13.91B$10.10B
Net debt-$5.08B————
Shares outstanding253.99M256.94M257.70M257.01M254.48M
Cash flow statement
Operating cash flow$3.63B-$492.60M$3.54B$4.13B$2.64B
Capital expenditure$437.60M$297.70M$200.40M$204.70M$235.00M
Free cash flow$3.19B-$790.30M$3.34B$3.93B$2.41B
Investing cash flow-$945.40M-$3.77B-$3.14B-$321.10M-$340.90M
Financing cash flow-$2.26B-$1.49B-$562.20M-$67.70M-$1.48B
Depreciation & amortization$209.80M$207.20M$181.30M$148.30M$125.60M
Stock-based compensation$685.90M$698.50M$581.20M$491.30M$441.40M
Share buybacks$2.02B$1.18B$427.60M$0$1.43B

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.